Pfizer, Wave team on metabolic therapy | Chemical & Engineering News
Volume 94 Issue 20 | p. 17 | Concentrates
Issue Date: May 16, 2016

Pfizer, Wave team on metabolic therapy

Department: Business
Keywords: pharmaceuticals, research, licensing, metabolic diseases, liver

Pfizer and Wave Life Sciences are joining to develop nucleic acid therapies targeting metabolic diseases. The partners will combine Wave’s stereopure drug development platform with Pfizer’s hepatic targeting technology for enhancing delivery to the liver. Pfizer will advance up to five programs from discovery through selection of clinical candidates, at which point it can license programs. Two targets have been declared. Wave will get $40 million up front and could take in $187 million if all five programs are successful.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment